Open house drug discount agreements Risankizumab, ATC L04AC18

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Oct 03, 2027 · 401 days left·Open·Supplies·Framework

Structured notice only

Original notice title

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Risankizumab, ATC L04AC18

50/100

Opportunity Score

Needs reviewLow complexity

SuppliesFrameworkOpen

Why this score?

Opportunity

50 / 100

Complexity

20 / 100

Risk factors

The open-house model does not guarantee any minimum purchase volume; revenue depends on actual prescriptions.

If a non-exclusive discount contract for the same substance is concluded via a public procurement, this open-house agre...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

Description
Industries & Services
Capabilities
Market & Experience
Certifications

Overview

Moderate opportunity

Key Facts

Framework procurement
Supplies contract
1 lot
Duration until Nov 2027
Non-exclusive discount agreements for pharmaceutical products containing Risankizumab (ATC L04AC18)
Contracts are identical and non-negotiable for all participants

Show full summary

This is an open-house procedure by AOK Bayern for non-exclusive discount agreements on Risankizumab (ATC L04AC18) under §130a SGB V. It is not a public procurement but a voluntary participation model open to all pharmaceutical companies that meet eligibility criteria. Contracts can be concluded anytime until 03.10.2027, with a minimum term until 30.11.2027. No estimated value or award criteria are defined; all eligible participants receive a contract.

Risks

The open-house model does not guarantee any minimum purchase volume; revenue depends on actual prescriptions.

If a non-exclusive discount contract for the same substance is concluded via a public procurement, this open-house agre...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Eligibility

Only pharmaceutical companies are eligible to participate

Administrative

Submit a signed declaration of reliability
Submit the signed contract and annex 'Determination of the contract-related medicinal products'

Requirements may be incomplete.

Award Criteria

Lot 1

No explicit award criteria - open house model, all eligible participants get a contract.

Buyer

Name

AOK Bayern - Die Gesundheitskasse

Location

München, DEU

[email protected]

Website

www.aok.de

Buyer profile

Open profile

Identifier

DE811695320

Activity

Health

Lots (1)

LOT-0001

Open house drug discount agreements Risankizumab, ATC L04AC18

Non-exclusive discount agreements for the active substance Risankizumab, ATC L04AC18, in Germany. Contract term from 01.12.2025 to 30.11.2027. No selection process; all pharmaceutical companies meeting eligibility can join.

SuppliesFrameworkEU fundedElectronic submission

Location

DE212, Germany

Duration

Nov 2025 - Nov 2027

Procurement Details

Publication date: 13 Oct 2025
Languages: German

Reference metadata

Legal basis: 32014L0024

Reference IDs

Tender ID: 675355-2025

Documents (2)

Procurement document 1 Submission portal 1

Similar tenders

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3